This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dynavax, Santarus: Early Volume Plays

NEW YORK ( TheStreet) -- Dynavax was among several stocks trading near $5poised to surge on heavy volume after clinical data showed its experimental hepatitis B vaccine showed promise in treating chronic kidney disease.

Dynavax said Phase II trials "demonstrate HEPLISAV 's immunogenicity and rapid protection in patients with chronic kidney disease." Dynavax said results showed that two doses of HEPLISAV protected 100% of the dialysis and pre-dialysis patients measured at week 24 in the Phase II study.

After closing at $1.45 Wednesday, Dynavax shares rallied by 35 cents, or 24.1%, to $1.80 in Thursday's premarket session. The 50-day average daily volume for Dynavax is 326,000, according to the Nasdaq.

CompuCredit Holdings (CCRT) was also indicated to trade higher on increased volume after the financial services said it will hold a modified Dutch auction tender offer for both debt and stock. CompuCredit said the offer is to purchase up to $100 million of its outstanding 3.625% convertible senior notes, as well as shares of outstanding common stock at a purchase price of $7 per share if there is money left over from the note purchase.

CompuCredit shares closed at $5.56 Wednesday and rose nearly 17% in the after-market session to $6.50. The 50-day average daily volume for CompuCredit is 100,000.

On the other hand, Santarus (SNTS) should lose ground on above-average volume after the U.S. District Court for the District of Delaware ruled that five patents covering Santarus' prescription products are invalid due to obviousness. Par Pharmaceutical (PRX) brought the lawsuit against Santarus.

Santarus shares were plummeting by $2.28, or 42.5%, to $3.08 in Thursday's premarket session. The 50-day average daily volume for Santarus is 437,000.

The Princton Review (REVU) was also poised to trade lower after the company announced an offering of 14 million common shares. After finishing Wednesday's session at $3.47, the stock fell 6.9% to $3.23 in late trading. The 50-day average daily volume for the Princeton Review is 63,000.

-- Written by Robert Holmes in Boston.

Check out all of Thursday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SNTS $0.00 0.00%
DVAX $22.70 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs